Breyanzi® (lisocabtagene maraleucel) – New indication
May 30, 2024 - Bristol Myers Squibb announced the FDA approval of Breyanzi (lisocabtagene maraleucel), for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor.
Top